In the BioHarmony Drug Report Database

"Preview" Icon

Cetuximab

Erbitux (cetuximab) is an antibody pharmaceutical. Cetuximab was first approved as Erbitux on 2004-02-12. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat colorectal neoplasms and head and neck neoplasms. The pharmaceutical is active against epidermal growth factor receptor.

 

Trade Name

 

Erbitux
 

Common Name

 

cetuximab
 

ChEMBL ID

 

CHEMBL1201577
 

Indication

 

colorectal neoplasms, head and neck neoplasms, squamous cell carcinoma
 

Drug Class

 

Monoclonal antibodies: chimeric, tumors as target

Image (chem structure or protein)

Cetuximab structure rendering